 |
 Video: What is a Stock Split?
|
|
|
| KemPharm is a specialty pharmaceutical company focused on the discovery and development of treatments for central nervous system (CNS) and rare disease indications that allow it to target areas with unmet needs. Co.'s prodrug product candidate pipeline is focused on the idiopathic hypersomnia (IH) and other CNS/rare diseases. Co.'s approved product, AZSTARYS®, a once-daily treatment for attention deficit hyperactivity disorder in patients, age six years and older, contains its prodrug, serdexmethylphenidate (SDX). Co.'s primary clinical development product candidate, KP1077, is based on SDX, its prodrug of d-methlyphenidate and is in development for the treatment of IH and narcolepsy. According to our KMPH stock split history records, KMPH has had 0 splits. | |
|
KMPH (KMPH) has 0 splits in our KMPH stock split history database.
Looking at the KMPH stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into KMPH shares, starting with a $10,000 purchase of KMPH, presented on a split-history-adjusted basis factoring in the complete KMPH stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/17/2015 |
|
| End date: |
02/28/2023 |
|
| Start price/share: |
$11.10 |
|
| End price/share: |
$5.81 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-47.66% |
|
| Average Annual Total Return: |
-7.89% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$5,235.43 |
|
| Years: |
7.87 |
|
|
|
|
|
